|
204
|
| 825 |
HBEGF
|
|
affects_quantity of
|
Serotonin
|
|
|
19829704
|
Schizophrenia
|
|
596
|
| 3152 |
Pilocarpine
|
|
increases_quantity of
|
Serotonin
|
in acute stage of status epilepticus in pilocarpine model
|
|
8112229
|
Status epilepticus
|
|
3,884
|
| 39206 |
Fenofibrate
|
|
decreases_quantity of
|
Serotonin
|
in urine
|
|
19458390
|
Diabetes mellitus, type II
Lipodystrophy
Insulin resistance
|
|
4,133
|
| 42565 |
LEP
|
|
decreases_quantity of
|
Serotonin
|
in the paraventricular nucleus
|
|
16210420
|
Neurological
|
|
4,356
|
| 44493 |
HTR1A
|
|
interacts (colocalizes) with
|
Serotonin
|
|
| 44494 |
HTR2A
|
|
interacts (colocalizes) with
|
Serotonin
|
|
| 44495 |
HTR2C
|
|
interacts (colocalizes) with
|
Serotonin
|
|
|
6757812
|
Mental
|
|
4,463
|
| 44992 |
ALDH2
|
|
decreases_quantity of
|
Serotonin
|
in hamster liver mitochondria; to 5-HIAA (5-hydroxyindole-3-acetic acid)
|
| 44993 |
MAOB
|
|
decreases_quantity of
|
Serotonin
|
in hamster liver mitochondria; to 5-HIAA (5-hydroxyindole-3-acetic acid)
|
|
11063613
|
Metabolic
|
|
4,465
|
| 45000 |
Serotonin
|
|
increases_activity of
|
Wnt signaling pathway
|
|
|
22177902
|
Metabolic
|
|
4,466
|
| 45002 |
MCHR1
|
|
increases_quantity of
|
Serotonin
|
in the prefrontal cortex (PFC)
|
| 106724 |
MCHR1 KO mouse
|
|
decreases_quantity of
|
Serotonin
|
in the prefrontal cortex (PFC); compared with wild-type controls
|
|
15988472
|
Neurological
Metabolic
|
|
4,764
|
| 47183 |
Serotonin
|
|
decreases_activity of
|
vasodilation
|
|
| 47205 |
platelet aggregation
|
|
increases_quantity of
|
Serotonin
|
|
|
2782444
|
Cardiovascular disease
|
|
4,765
|
| 47184 |
Serotonin
|
|
interacts (colocalizes) with
|
NOS1
|
but only when the enzyme is active and in a superoxide-dependent manner, resulting in increased levels of ROS
|
| 47186 |
Serotonin
|
|
increases_quantity of
|
Reactive oxygen species
|
in the presence of nNOS
|
|
19191108
|
Metabolic
Cardiovascular disease
|
|
4,767
|
| 47193 |
Serotonin
|
|
increases_quantity of
|
NO
|
in endothelial cells
|
| 47194 |
Serotonin
|
|
increases_quantity of
|
Reactive oxygen species
|
if only low concentrations of serotonin were present
|
| 47196 |
Serotonin
|
|
increases_activity of
|
NOS1
|
in the absence of arginine
|
|
17454123
|
Metabolic
Cardiovascular disease
|
|
4,768
|
| 47204 |
DDC
|
|
increases_quantity of
|
Serotonin
|
|
| 47779 |
TPH
|
|
increases_quantity of
|
Serotonin
|
|
| 47780 |
Tryptophan
|
|
increases_quantity of
|
Serotonin
|
|
|
24170240
|
Metabolic
Cardiovascular disease
|
|
4,769
|
| 47207 |
Serotonin
|
|
decreases_activity of
|
vasodilation
|
via 5-HT2A receptors in smooth muscle cells
|
| 47208 |
Serotonin
|
|
increases_activity of
|
vasodilation
|
via 5-HT1B receptors in endothelial cells, through activating nitric oxide synthase
|
| 47209 |
Serotonin
|
|
increases_activity of
|
NOS3
|
in endothelial cells
|
| 47211 |
cardiac ischemia
|
|
increases_quantity of
|
Serotonin
|
in blood plasma
|
|
15572052
|
Cardiovascular disease
|
|
5,011
|
| 49437 |
Beta blocker
|
|
decreases_quantity of
|
Serotonin
|
in blood serum
|
|
24816436
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,172
|
| 50763 |
Cocoa
|
|
increases_quantity of
|
Serotonin
|
in brain; of rats
|
|
23810791
|
Neurological
Alzheimer disease
|
|
5,409
|
| 52744 |
Serotonin
|
|
increases_quantity of
|
CTNNB1
|
in osteoblasts
|
| 52745 |
Serotonin
|
|
decreases_activity of
|
GSK3B
|
in osteoblasts; via increased phosphorylation
|
|
23619963
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,416
|
| 52908 |
Serotonin
|
|
increases_activity of
|
HTR1B
|
in osteoblasts
|
| 52909 |
Serotonin
|
|
increases_activity of
|
CREB1
|
in osteoblasts
|
| 52910 |
Serotonin
|
|
decreases_activity of
|
osteoblast proliferation
|
|
|
19041748
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,421
|
| 52900 |
MAOB
|
|
decreases_quantity of
|
Serotonin
|
in cerebrospinal fluid in two male siblings and in their mother ; experimentally shown via MAO-A and MAO-B deletion
|
| 52901 |
MAOA
|
|
decreases_quantity of
|
Serotonin
|
in cerebrospinal fluid in two male siblings and in their mother ; experimentally shown via MAO-A and MAO-B deletion
|
| 102619 |
decreased MAOB level
|
|
increases_quantity of
|
Serotonin
|
in cerebrospinal fluid in two male siblings and in their mother
|
| 102620 |
decreased MAOA level
|
|
increases_quantity of
|
Serotonin
|
in cerebrospinal fluid in two male siblings and in their mother
|
|
23414621
|
Neurological
Metabolic
|
|
5,422
|
| 52902 |
MAOA
|
|
decreases_quantity of
|
Serotonin
|
|
| 52903 |
MAOB
|
|
decreases_quantity of
|
Serotonin
|
|
|
22964922
|
Metabolic
|
|
5,501
|
| 53425 |
Tetrahydrobiopterin
|
|
increases_quantity of
|
Serotonin
|
|
|
22729819
|
Metabolic
|
|
6,166
|
| 61055 |
SLC6A4
|
|
increases_transport of
|
Serotonin
|
|
|
22457503
|
Neurological
|
|
6,306
|
| 59062 |
Ondansetron
|
|
decreases_activity of
|
Serotonin
|
|
|
25098424
|
Cancer
Leukemia
|
|
6,307
|
| 59063 |
Serotonin
|
|
decreases_activity of
|
apoptotic cell clearance
|
via RHOA and ROCK
|
| 59066 |
Serotonin
|
|
increases_phosphorylation of
|
PPP1R12A
|
at Thr696
|
| 59071 |
Serotonin
|
|
increases_activity of
|
ROCK
|
|
|
24570000
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
6,326
|
| 59383 |
Serotonin
|
|
decreases_quantity of
|
IRS1
|
in 3T3-L1 adipocytes
|
| 59384 |
Serotonin
|
|
decreases_phosphorylation of
|
AKT1
|
in 3T3-L1 adipocytes
|
| 59385 |
Serotonin
|
|
decreases_activity of
|
glucose import
|
in 3T3-L1 adipocytes
|
| 59386 |
Serotonin
|
|
decreases_phosphorylation of
|
IRS1
|
in 3T3-L1 adipocytes; at tyrosine residues
|
| 59387 |
Serotonin
|
|
decreases_quantity of
|
PIK3R1-IRS1 complex
|
in 3T3-L1 adipocytes
|
| 59388 |
Serotonin
|
|
decreases_activity of
|
insulin receptor signaling pathway
|
in 3T3-L1 adipocytes
|
|
22975078
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,327
|
| 59389 |
Diabetes mellitus, type II
|
|
increases_quantity of
|
Serotonin
|
in blood plasma
|
|
7992257
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,328
|
| 59390 |
MAOB
|
|
decreases_quantity of
|
Serotonin
|
|
|
9383015
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,330
|
| 59485 |
Serotonin
|
|
decreases_activity of
|
insulin secretion
|
in non-diabetic probands
|
| 59486 |
Serotonin
|
|
decreases_activity of
|
glucagon secretion
|
in non-diabetic probands
|
| 59487 |
Serotonin
|
|
increases_activity of
|
insulin secretion
|
in diabetic probands
|
|
26206285
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,331
|
| 59395 |
Serotonin
|
|
increases_activity of
|
increased tumor growth/size
|
in Huh7 and HepG2 hepatocellular cancer cells
|
| 59397 |
Serotonin
|
|
decreases_activity of
|
autophagy
|
in Huh7 and HepG2 hepatocellular cancer cells; in response to starvation
|
|
20099302
|
Hepatocellular carcinoma
|
|
6,332
|
| 59400 |
Serotonin
|
|
increases_activity of
|
melanin biosynthetic process
|
in skin, in B16F10, SK-MEL-2 and Melan-A cells
|
|
21711335
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,333
|
| 59407 |
HTR2A
|
|
interacts (colocalizes) with
|
Serotonin
|
|
|
21711335
|
Diabetes mellitus, type II
Insulin resistance
|
CIDeRplus